Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy?
- PMID: 27083274
- DOI: 10.1016/j.kint.2016.01.019
Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy?
Abstract
Patients with nephrotic syndrome are at increased risk of thrombosis. The risk of venous thrombosis is particularly high in patients with nephrotic syndrome due to primary membranous nephropathy. Recent data provide evidence that these patients also have a high absolute risk of arterial thrombotic events, which is associated with the degree of hypoalbuminemia. In this commentary we discuss whether prophylactic aspirin therapy might be indicated in this patient population.
Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
Comment on
-
Patients with primary membranous nephropathy are at high risk of cardiovascular events.Kidney Int. 2016 May;89(5):1111-1118. doi: 10.1016/j.kint.2015.12.041. Epub 2016 Feb 26. Kidney Int. 2016. PMID: 26924046 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
